Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Graphite Bio Inc (GRPH)

Graphite Bio Inc (GRPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 185,194
  • Shares Outstanding, K 58,237
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,650 K
  • 60-Month Beta 0.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.01
Trade GRPH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.88
  • Most Recent Earnings $-0.19 on 11/13/23
  • Latest Earnings Date 03/25/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +227,145.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.57 +23.74%
on 03/19/24
4.26 -25.35%
on 03/11/24
+0.18 (+6.00%)
since 02/21/24
3-Month
2.33 +36.48%
on 12/22/23
4.26 -25.35%
on 03/11/24
+0.83 (+35.32%)
since 12/21/23
52-Week
2.01 +58.20%
on 11/15/23
4.26 -25.35%
on 03/11/24
+0.85 (+36.48%)
since 03/21/23

Most Recent Stories

More News
Should You Buy Graphite Bio (GRPH) Ahead of Earnings?

Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GRPH : 3.18 (-2.75%)
Beat the Market Like Zacks: NVIDIA, Clorox, Procter & Gamble in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

NVO : 122.71 (-0.03%)
PG : 158.14 (+0.54%)
FAST : 67.57 (+0.10%)
OMC : 92.62 (+1.22%)
NVDA : 762.00 (-10.00%)
CLX : 143.55 (+0.24%)
MKC : 73.92 (+1.68%)
TAST : 9.52 (+0.21%)
NOBL : 97.03 (+0.70%)
TELNY : 11.2400 (+1.63%)
GRPH : 3.18 (-2.75%)
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results

Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results.

GRPH : 3.18 (-2.75%)
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring

Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue...

GRPH : 3.18 (-2.75%)
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

GRPH : 3.18 (-2.75%)
Pre-Market Brief: Stocks Move Higher Ahead Of Key U.S. Payrolls Data

March S&P 500 futures (ESH23) are trending up +0.13% this morning after three major U.S. benchmark indices finished the regular session in the red as stronger-than-expected U.S. labor market data stoked...

ESH23 : 3,957.05s (-0.09%)
CTMX : 1.6700 (-3.47%)
FATE : 4.79 (-4.96%)
GRPH : 3.18 (-2.75%)
COST : 709.51 (-0.24%)
SPRB : 0.7004 (-0.09%)
WWE : 100.65 (+2.65%)
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease

Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event...

GRPH : 3.18 (-2.75%)
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat...

GRPH : 3.18 (-2.75%)
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat...

GRPH : 3.18 (-2.75%)
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat...

GRPH : 3.18 (-2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Graphite Bio Inc. is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 3.44
2nd Resistance Point 3.34
1st Resistance Point 3.26
Last Price 3.18
1st Support Level 3.08
2nd Support Level 2.97
3rd Support Level 2.89

See More

52-Week High 4.26
Fibonacci 61.8% 3.40
Last Price 3.18
Fibonacci 50% 3.14
Fibonacci 38.2% 2.87
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar